Elm Street Ventures

Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.

Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.

Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.

Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

Saphlux, Inc. develops, produces, and commercializes semi-polar gallium nitride (GaN) materials that solve droop and green gap problems in LEDs and lasers. The company offers semi-polar GaN templates in two diameters or customized size (quarters). Saphlux, Inc. was founded in 2014 and is based in New Haven, Connecticut.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

SeeClickFix, Inc. is a communications platform designed to facilitate reporting of non-emergency issues by citizens and to enable governments to manage and respond effectively. Founded in 2007 and headquartered in New Haven, Connecticut, the company provides several tools aimed at enhancing civic engagement and government transparency. Its offerings include Request Management for gathering data and tracking work orders, Work Management for optimizing internal communication and assignments, and Citizen Engagement tools to inform and involve local communities. Additionally, SeeClickFix provides analytics tools that help assess public service performance and guide decision-making. The platform caters to various sizes and budgets, empowering residents, community organizations, and government officials to collaboratively enhance their neighborhoods. SeeClickFix operates as a subsidiary of CivicPlus, LLC.

Device42, Inc. is a provider of software solutions aimed at system, network, and data center engineers, as well as IT managers. Founded in 2010 and based in West Haven, Connecticut, with an additional office in Boston, the company specializes in hybrid IT discovery and application dependency mapping. Its offerings include Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and data center infrastructure management solutions. Device42’s software enables organizations to maintain an accurate inventory of both IP-based and non-IP assets, covering physical, logical, and virtual devices. The platform supports various functionalities such as IT asset management, patch panel cable management, and enterprise password management, facilitating efficient management of infrastructure and applications across data centers and cloud environments. By integrating with existing service management and DevOps tools, Device42 helps clients optimize their IT operations and ensure compliance with internal and external regulations.

Device42, Inc. is a provider of software solutions aimed at system, network, and data center engineers, as well as IT managers. Founded in 2010 and based in West Haven, Connecticut, with an additional office in Boston, the company specializes in hybrid IT discovery and application dependency mapping. Its offerings include Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and data center infrastructure management solutions. Device42’s software enables organizations to maintain an accurate inventory of both IP-based and non-IP assets, covering physical, logical, and virtual devices. The platform supports various functionalities such as IT asset management, patch panel cable management, and enterprise password management, facilitating efficient management of infrastructure and applications across data centers and cloud environments. By integrating with existing service management and DevOps tools, Device42 helps clients optimize their IT operations and ensure compliance with internal and external regulations.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

P2 Science, Inc. is a bio-renewable chemistry company based in Woodbridge, Connecticut, specializing in the development and production of specialty chemicals derived from renewable feedstocks, such as vegetable oils. Founded in 2009 by a team that includes Yale scientists and an experienced chemical industry executive, the company focuses on creating high-value ingredients for flavors, fragrances, cosmetics, and other applications. P2 Science aims to provide sustainable alternatives to traditional petrochemical products, catering to diverse markets, including personal care, household cleaning, agriculture, and environmental remediation. Their innovative technology enables the conversion of renewable resources into cost-effective chemical solutions, addressing the increasing demand for greener options among major users in the specialty chemicals sector. The company also maintains a laboratory in New Haven, Connecticut, to support ongoing research and partnerships throughout the supply chain.

Accelerated Orthopedic Technologies, Inc., based in Guilford, Connecticut, specializes in developing proprietary instruments designed to treat articular cartilage defects. The company offers custom-sized tools that match the topography required for effective cartilage grafting. Founded in 2009 and originally known as Advanced Orthopedic Technologies, the company rebranded in February 2010. Its innovative approach aims to improve outcomes in orthopedic procedures by providing tailored solutions for cartilage repair.

Metagenomix is an early-stage biotechnology company developing novel methods of screening microbes for pharmacologically active compounds. Among the indications under investigation are cancer, inflammation and infectious diseases including fungal infections and malaria. The technology also has applications in agriculture.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK, currently undergoing Phase I clinical trials for advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as an antibody-drug conjugate known as KIT-ADC for oncology applications. The company also engages in various research programs targeting RTKs, building on foundational discoveries made in collaboration with Dr. Joseph Schlessinger's laboratory at Yale University, which elucidate the molecular mechanisms linked to RTK activation and oncogenic mutations.

Retail Optimization Inc. specializes in predictive macro optimization analytics aimed at improving profitability in retail environments. The company offers solutions for space management, store remodeling, and assortment planning, enabling retailers and suppliers to identify optimal product selection, category space, and inventory investment. Their software integrates various elements, including consumer insights, supply chain dynamics, market data, and store layouts, to enhance the overall shopping experience for consumers. By leveraging these analytics, retailers can make informed decisions about category, aisle, department, and store size, ultimately driving efficiency and effectiveness in their operations.

Affomix is a biotechnology company specializing in the development of antibody-based products. Utilizing proprietary technology, it offers rapid and automated high-throughput selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, along with mAb microarrays and mAb libraries, for various applications in research, drug discovery, diagnostics, and therapeutics. Affomix aims to enhance the sensitivity and accuracy in measuring large numbers of proteins in biological samples, leveraging its capabilities to produce and screen antibodies against virtually all human proteins, including those that are post-translationally modified.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.